Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 21st European Biotechnology Congress Holiday Inn Vinogradovo, Moscow, Russia.

Day 1 :

Keynote Forum

Vladimir P Torchilin

Northeastern University, USA

Keynote: Next Step in drug delivery: Getting Inside cells and to individual organelles

Time : 10:00-10:40

OMICS International Euro Biotechnology 2018 International Conference Keynote Speaker Vladimir P Torchilin photo
Biography:

Vladimir P Torchilin PhD DSc, is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews
and book chapters, wrote and edited 12 books, and hold more than 40 patents. Google Scholar shows more than 55,000 citations of his papers with H-index of 105. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30M from the governmental and industrial sources in research funding. He
has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

Abstract:

There are already some means to deliver drugs inside cells bypassing the lysosomal degradation. Thus, coupling of cellpenetrating
peptides (CPP) to various molecules, including peptides and proteins, or even to nanoparticles, such as
liposomes, dramatically facilitates their intracellular delivery. Similar effect could be achieved using phage coat fusion proteins
purified from the phages selected for their specificity towards certain target cells as was shown with liposome-loaded anticancer
drugs. The combination of targeted delivery of drug-loaded nanopreparations to target cells and their subsequent delivery
inside cells might still further improve the efficiency of therapy. Intracellular drug delivery with subsequent organelle targeting
opens new opportunities in overcoming problems associated with multiple pathologies including lysosomal storage diseases
and multidrug resistance (MDR) tumors. Delivery of deficient enzymes for the treatment of lysosomal diseases evidently
requires specific targeting of lysosomes, while facilitating apoptotic cell death in MDR tumor would require targeting of
mitochondria or lysosomes. Thus, next generation drug delivery systems should be able to target individual organelles inside
cells. Clearly, this challenge will require some novel approaches in engineering multifunctional nanomedicines, capable of
accumulating in the target tissue, penetrating inside cells, bypassing lysosomes, and bringing pharmaceuticals to individual
organelles. Examples of specific targeting of pharmaceutical nanocarriers loaded with pharmaceutical agents to lysosomes and
mitochondria in cells illustrate the benefits of this new approach.

OMICS International Euro Biotechnology 2018 International Conference Keynote Speaker Sergey Suchkov photo
Biography:

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD and maintained his PhD and Doctor’s degree. He was working for Helmholtz Eye Research Institute and Moscow Regional Clinical Research Institute. He was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Currently, he is a Director of Center for Personalized Medicine, Sechenov University; Chair of the Department for Translational Medicine, Moscow Engineering
Physics University and Secretary General of United Cultural Convention, Cambridge, UK. He is a Member of the New York Academy of Sciences; American Chemical Society; American Heart Association; AMEE, Dundee, UK; EPMA, Brussels, EU; PMC, Washington, DC, USA and ISPM, Tokyo,
Japan.

Abstract:

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized
medicine (PM). To achieve the implementation of PM concept into the daily practice including clinical cardiology, it is
necessary to create a fundamentally new strategy based upon the subclinical recognition of bioindicators (biopredictors and
biomarkers) of hidden abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact
of their decision to use PM on their own budget and well-being, which may not necessarily be optimal for society as a whole.
It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and
personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting
in improved outcomes whilst securing the healthy state and wellness, reduced adverse events, and more cost effective use of
health care resources. One of the most advanced areas in cardiology is atherosclerosis, cardiovascular and coronary disorders
as well as in myocarditis. A lack of medical guidelines has been identified by the majority of responders as the predominant
barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of
PM into the daily practice of cardiologists! Implementation of PM requires a lot before the current model “physician-patient”
could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global
sci-entific, clinical, social, and educational projects in the area of PM to elicit the content of the new branch.

Keynote Forum

Igor l Katkov

Belgorod National State Research University, Russian Federation

Keynote: Stopping biological time: Science and art of biostabilization

Time : 11:40-12:20

OMICS International Euro Biotechnology 2018 International Conference Keynote Speaker Igor l Katkov photo
Biography:

Igor L Katkov is a trained biophysicist with 30+ years of experience in cryobiology and cryogenic engineering. His last years of research have been focused on the fundamental aspects of kinetic vitrification (K-VF) as well on designing the practical system for K-VF KrioBlast™ (in cooperation with V F Bolyukh). Currently, the Head of the Laboratory of the Amorphous state at the Belgorod National Research University BelSU, Russia. He has recently accepted a
Professor level position as the Head of the Laboratory of Cryobiology at the V I Kulakov Research Center of Obstetrics, Gynecology and Perinatology (RCGOP), Moscow, Russia and Chief Scientific Officer of Celltronix, San Diego, CA, USA.

Abstract:

Biostabilization (a.k.a. biopreservation) is a process that leads to cessation of the basic chemical and biological reactions
so the biosamples can be pooled and stored (biobanked) for long time. There are 5 basics ways of achieving long-term
storage, which ALL essentially lead to vitrification of cells, namely: slow freezing (SF), equilibrium vitrification (E-VF), kinetic
vitrification (K-VF), freeze-drying (lyophilization) and vacuum/air flow drying at temperatures above 0°C (xeropreservation).
Different combinations of the 5 basic biopreservation technologies such a preliminary drying before cryogenic slow freezing
or vitrification is also possible. Author will discuss a phase diagram that shows all 5 basic ways of biostabilization and will
discuss pros and cons of all approaches. A special emphasis will be put on the kinetic vitrification as it does not require the
high concentrations of (or does not need at all) potentially toxic and osmotically damaging exogenous permeable intracellular
vitrificants (also called cryoprotectants). Author will also present KrioBlast-2, a pilot version of the KrioBlast™ platform for
cryopreservation by K-VF. Preliminary experiments on K-VF of human pluripotent stem cells and spermatozoa, which
showed an equally excellent (80-90% of the untreated control) will be also discussed. A more advanced version KrioBlast-3
will be discussed in the concurrent presentation.